Bevacizumab versus placebo in combination with paclitaxel and carboplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase II trial-Reference-Cited by-同舟云学术

Bevacizumab versus placebo in combination with paclitaxel and carboplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase II trial

Published:2021-12 Issue:6 Volume:6 Page:100313
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Zhou T.,Yang Y.,Ma S.,Lin L.,Zhou T.,Zhang C.,Ding X.,Wang R.,Feng G.,Chen Y.,Xu R.,Huang Y.,Zhang L.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference32 articles.

1. Nasopharyngeal carcinoma;Chua;Lancet,2016

2. Nasopharyngeal cancer and the Southeast Asian patient;Her;Am Fam Physician,2001

3. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012;Ferlay;Int J Cancer,2015

4. Prospective study of tailoring whole-body dual-modality [18F]fluorodeoxyglucose positron emission tomography/computed tomography with plasma Epstein-Barr virus DNA for detecting distant metastasis in endemic nasopharyngeal carcinoma at initial staging;Tang;J Clin Oncol,2013

5. Distant metastasis risk and patterns of nasopharyngeal carcinoma in the era of IMRT: long-term results and benefits of chemotherapy;Li;Oncotarget,2015

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Galunisertib promotes bevacizumab-induced vascular normalization in nasopharyngeal carcinoma: Multi-parameter MRI evaluation;Molecular Therapy: Oncology;2024-09

2. Failure patterns and individualized treatment plans of reirradiation for inoperable locally recurrent nasopharyngeal carcinoma;Scientific Reports;2024-08-02

3. Angiogenesis in nasopharyngeal carcinoma: insights, imaging, and therapeutic strategies;Frontiers in Oncology;2024-05-28

4. Progress of Angiogenesis Signal Pathway and Antiangiogenic Drugs in Nasopharyngeal Carcinoma;Current Molecular Pharmacology;2024-05-17

5. Anlotinib as a third-line or further treatment for recurrent or metastatic nasopharyngeal carcinoma: a single-arm, phase 2 clinical trial;BMC Medicine;2023-11-07